February 13, 2022 /
MS Research Study and Reports
January 20, 2022 04:26 PM Eastern Standard Time
METUCHEN, N.J.–(BUSINESS WIRE)–Tevogen Bio, a clinical stage biotechnology company specializing in cell and gene therapies in oncology and viral infections, today announced its intention to study its proprietary off-the-shelf T cell technology to develop therapeutic solutions for multiple sclerosis (MS) by developing Epstein-Barr virus (EBV) specific CD8+ cytotoxic T lymphocytes (CTL). Multiple sclerosis is a chronic inflammatory disease of the central nervous system, for which there is currently no definitive cure.
“Recent studies on multiple sclerosis have suggested a probable link between latent infection with EBV and later onset of the inflammation that degrades the myelin sheath and causes multiple sclerosis,” said Neal Flomenberg, M.D., Chairman of Tevogen’s Scientific Advisory Board. “We look to apply our significant expertise in off-the-shelf allogeneic SARS-CoV-2 specific CD8+ cytotoxic T lymphocytes (CTLs) to explore EBV specific CTL therapy as a possible means of addressing the unmet needs of MS patients,” Flomenberg added.
“Anyone that knows someone who has been impacted by this debilitating disease understands the importance of advancing science to develop pathways to alleviate the suffering from MS,” said Tevogen CEO Ryan Saadi, M.D., M.P.H. “I’m hopeful that our disruptive T cell technology will eventually offer accessible immunotherapies to millions suffering from viral infections, cancers and other diseases with high unmet need.”
About Tevogen’s Investigational T Cell Therapy for COVID-19
Tevogen’s investigational T cell therapy for COVID-19, TVGN-489, is currently undergoing proof of concept clinical trial at Jefferson University Hospitals in Philadelphia. Trial details are available at Clinical Trials – Tevogen.
TVGN-489 is a highly purified, SARS-CoV-2-specific cytotoxic CD8+ T lymphocyte product, which detects targets spread across the entire viral genome. These targeted CTLs are expected to recognize and kill off virally infected cells, allowing the body to replace them with healthy, uninfected cells. TVGN-489 demonstrated strong activity against SARS-CoV-2 targets in preclinical studies.
Click to Subscribe for the MS Beacon eNewsletter and MS educational events
|
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
Stay informed with MS news and information - Sign-up here
For MS patients, caregivers or clinicians, Care to chat about MS? Join Our online COMMUNITY CHAT
Categories
Latest Blog Posts
- UIC Study: Remote Pilates Program for People Living with MS
- Exercise and Cognition in Multiple Sclerosis in 2025: Forward Momentum or Going Nowhere Fast?
- Safety, adherence, and compliance in a RCT of supervised exercise training among persons with multiple sclerosis who have slowed cognitive processing speed
- Trigeminal neuralgia and MS
- What Is an MS Zinger and How Can You Manage It?
- What to know about itching and MS
- Two compounds with potential for myelin repair in MS identified
- Losing my sense of safety after an MS relapse
- 7 Ways to Navigate Your Health Insurance With MS
- Big Changes Are Coming for 2026 Medicare Plans. What You Need to Know.
- Exercise in MS eases fatigue, improves muscular fitness: Analysis
- Could Ultra-Processed Foods Make Your MS Worse?
- VIRTUAL Physical Therapy – (each month) – “MOVING WITH MS” –
- The New MS Diagnostic Criteria: What You Need To Know
- Octave wins grant to develop blood test for measuring MS progression
- With new data, Quantum moves closer to launching trial of Lucid-MS – a potential treatment for targeting demyelination
- When living with MS, we have to be open to change in our routine
- ECTRIMS 2025: Immunic chief medical officer discusses vidofludimus calcium for MS
- ECTRIMS 2025: Medical director at Genentech discusses potential of Ocrevus as a pediatric MS treatment
- Maternal and neonatal outcomes associated with natalizumab exposure during pregnancy in patients with multiple sclerosis
